Literature DB >> 12545074

Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation.

Regina Hofmann-Lehmann1, Josef Vlasak, Alison L Williams, Agnès-Laurence Chenine, Harold M McClure, Daniel C Anderson, Shawn O'Neil, Ruth M Ruprecht.   

Abstract

OBJECTIVE: A live attenuated SIV vaccine strain, termed SIVmac239Delta3 and containing large deletions in, and the negative regulatory element, was previously shown to cause AIDS mostly in monkeys vaccinated as infants. In the present study, we demonstrate that SIVmac239Delta3 is pathogenic in most vaccinated adult monkeys, given enough time.
METHODS: Eleven rhesus macaques vaccinated as adults with SIVmac239Delta3 were followed for extended periods (up to 6.8 years).
RESULTS: We found signs of immune dysregulation in all 11 adult vaccinees. All animals developed persistently inverted CD4 : CD8 T-cell ratios, seven (64%) had persistent recurrent viremia, and six (55%) had decreased CD4 T-cell counts (< 500 x 10 cells/l). Further signs included low CD4CD29 lymphocyte subsets, loss of anti-Gag antibodies, anemia, thrombocytopenia, wasting, and opportunistic infections. Two adult vaccinees (18%) subsequently developed AIDS. Development of chronic, recurrent viremia with plasma viral RNA loads > or = 10 copies/ml and cytoviremia was a poor prognostic sign.
CONCLUSION: Our data demonstrate that with time, a live attenuated, multiply deleted SIV vaccine can cause immune dysregulation in most vaccine recipients, even in initially immune competent, healthy adults. Immune dysfunction can progress to full AIDS. However, pathogenic effects became evident only several years after vaccination. Thus, mass vaccination of humans with similarly constructed live attenuated HIV vaccines, recently suggested for countries with high HIV-1 transmission rates, seems contraindicated.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12545074     DOI: 10.1097/00002030-200301240-00004

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  50 in total

Review 1.  HIV-1 evolution: frustrating therapies, but disclosing molecular mechanisms.

Authors:  Atze T Das; Ben Berkhout
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2010-06-27       Impact factor: 6.237

Review 2.  Tetraspanins in viral infections: a fundamental role in viral biology?

Authors:  F Martin; D M Roth; D A Jans; C W Pouton; L J Partridge; P N Monk; G W Moseley
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

3.  Transcriptional activity of blood-and cerebrospinal fluid-derived nef/long-terminal repeat sequences isolated from a slow progressor infected with nef-deleted human immunodeficiency virus type 1 (HIV-1) who developed HIV-associated dementia.

Authors:  Melissa J Churchill; Anna Figueiredo; Daniel Cowley; Lachlan Gray; Damian Fj Purcell; John S Sullivan; Dale A McPhee; Steven L Wesselingh; Bruce J Brew; Paul R Gorry
Journal:  J Neurovirol       Date:  2006-06       Impact factor: 2.643

4.  Longitudinal analysis of human immunodeficiency virus type 1 nef/long terminal repeat sequences in a cohort of long-term survivors infected from a single source.

Authors:  Melissa J Churchill; David I Rhodes; Jennifer C Learmont; John S Sullivan; Steven L Wesselingh; Ian R C Cooke; Nicholas J Deacon; Paul R Gorry
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

5.  Understanding the failure of CD8+ T-cell vaccination against simian/human immunodeficiency virus.

Authors:  Rob J De Boer
Journal:  J Virol       Date:  2007-01-03       Impact factor: 5.103

Review 6.  DNA vaccines against human immunodeficiency virus type 1 in the past decade.

Authors:  Malavika Giri; Kenneth E Ugen; David B Weiner
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

Review 7.  Morphine and rapid disease progression in nonhuman primate model of AIDS: inverse correlation between disease progression and virus evolution.

Authors:  Vanessa Rivera-Amill; Peter S Silverstein; Richard J Noel; Santosh Kumar; Anil Kumar
Journal:  J Neuroimmune Pharmacol       Date:  2009-12-16       Impact factor: 4.147

8.  A consecutive priming-boosting vaccination of mice with simian immunodeficiency virus (SIV) gag/pol DNA and recombinant vaccinia virus strain DIs elicits effective anti-SIV immunity.

Authors:  Kenji Someya; Ke-Qin Xin; Kazuhiro Matsuo; Kenji Okuda; Naoki Yamamoto; Mitsuo Honda
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

9.  Impact of antibody quality and anamnestic response on viremia control post-challenge in a combined Tat/Env vaccine regimen in rhesus macaques.

Authors:  Thorsten Demberg; Egidio Brocca-Cofano; Seraphin Kuate; Stanley Aladi; Diego A Vargas-Inchaustegui; David Venzon; Irene Kalisz; V S Kalyanaraman; Eun Mi Lee; Ranajit Pal; Janet DiPasquale; Ruth M Ruprecht; David C Montefiori; Indresh Srivastava; Susan W Barnett; Marjorie Robert-Guroff
Journal:  Virology       Date:  2013-03-22       Impact factor: 3.616

10.  Role of complement and antibodies in controlling infection with pathogenic simian immunodeficiency virus (SIV) in macaques vaccinated with replication-deficient viral vectors.

Authors:  Barbara Falkensammer; Barbara Rubner; Alexander Hiltgartner; Doris Wilflingseder; Christiane Stahl Hennig; Seraphin Kuate; Klaus Uberla; Stephen Norley; Alexander Strasak; Paul Racz; Heribert Stoiber
Journal:  Retrovirology       Date:  2009-06-21       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.